Beta-Adrenergic Agonists

Barisione, Giovanni; Baroffio, Michele; Crimi, Emanuele; Brusasco, Vito

doi:10.3390/ph3041016

Cited by 83 publications

(67 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are 3 types of β‐AR: β1‐, β2‐, and β3. Among these, β1‐ and β2‐AR agonists are widely used against many clinical diseases, such as asthma, bradycardia, and chronic obstructive pulmonary disease (20). Recent reports have shown that β‐agonists activate the survival and proliferation pathways in many cell types, such as hemangioma‐derived ECs, tumor cells, and eosinophils (21–23).…”

mentioning

confidence: 99%

“…There are 3 types of b-AR: b1-, b2-, and ABBREVIATIONS: Akt, protein kinase B; Ang-2, angiopoietin 2; b-agonist, b-adrenergic receptor agonist; b-AR, b-adrenergic receptor; BRB, bloodretina barrier; DOB, dobutamine; DR, diabetic retinopathy; EC, endothelial cell; FOR, formoterol; FOX, forehead box; HbA1c, glycated hemoglobin A1c; HG, high glucose; HM, high mannitol; HRMEC, human retinal microvascular endothelial cell; IB, isolectin-B; ISO, isoproterenol; MTT, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NG, normal glucose; PARP, poly ADP-ribose polymerase; PC, pericyte; SAL, salbutamol; siRNA, small interfering RNA; STZ, streptozotocin; XAM, xamoterol; ZO-1, zona occludens-1 b3. Among these, b1and b2-AR agonists are widely used against many clinical diseases, such as asthma, bradycardia, and chronic obstructive pulmonary disease (20). Recent reports have shown that b-agonists activate the survival and proliferation pathways in many cell types, such as hemangioma-derived ECs, tumor cells, and eosinophils (21)(22)(23).…”

mentioning

confidence: 99%

See 1 more Smart Citation

β‐Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation

et al. 2017

View full text Add to dashboard Cite

Pericytes (PCs) are crucial in maintaining the quiescence of endothelial cells (ECs) and the integrity of EC tight junctions. Especially in diabetic retinopathy (DR), PC loss is one of the early pathologic changes in capillaries of diabetic retinas. Thus, preventing PC loss is beneficial for attenuating vision impairment in patients with DR. Although many studies have revealed the mechanism of PC loss in retinas, little is known about the mechanisms that increase PC survival. We focused on the effect of β-adrenergic receptor agonists (β-agonists) on PC loss in diabetic retinas. In this study, β-agonists increased the cell viability of PCs by increasing PC survival and proliferation. Mechanistically, β-agonist-induced protein kinase B activation in PCs reduced PC apoptosis in response to various stimuli. β2-agonists more potently increased PC survival than β1-agonists. β2-Agonist reduced vascular leakage and PC loss in retinas of mice with streptozotocin-induced diabetes. In cocultures of PCs and ECs, β2-agonists restored the altered permeability and ZO-1 expression in ECs induced by PC loss. We concluded that β-agonists, especially β2-agonists, increase PC survival, thereby preventing diabetes-induced PC loss in retinas. These results provide a potential therapeutic benefit of β-agonists for preventing PC loss in DR.-Yun, J.-H., Jeong, H.-S., Kim, K.-J., Han, M. H., Lee, E. H., Lee, K., Cho, C.-H. β-Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

β‐Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Long-acting β2 agonist is a drug of choice in the treatment of asthma to increase control symptoms. Inhaled β2-adrenoceptor (β2-AR) agonist is an important bronchodilator drug in the treatment of bronchial asthma, both as a symptom relievers and, in combination with inhaled corticosteroids, as disease control [29]. Beta 2 agonist is preventing bronchoconstriction induced by various stimuli excitatory airway mediators.…”

Section: Discussionmentioning

confidence: 99%

“…β-2 agonist is strong bronchodilator, and effective in the treatment of asthma due to beta-2 agonists play a role in dilating the smooth muscle of the bronchus. Stimulation β-2 adrenergic receptor activates adenylate cyclase, resulting in increased intracellular AMP cyclic and relaxation of smooth muscle [10].…”

Section: Introductionmentioning

confidence: 99%

Incidence of Hypertension in Asthma Patients Who Treated With Beta-2 Agonists Bronchodilators

Eff

2017

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: To determine the prevalence of hypertension in hospitalized patients with asthma who were treated with beta-2 agonists. To evaluate the correlation between the duration of the use of beta-2 agonist with the incidence of hypertension.Methods: This research is a descriptive epidemiological, observational cross-sectional and retrospective study design. The study population was all adult asthma patients (age ≥ 25) without a concomitant diseases such as hypertension or metabolic syndrome treated with β2 agonists as a bronchodilator and underwent hospitalized in January 2015-December 2015 (n=108). Patient data were collected from the medical record. Data were analyzed using univariate and bivariate to count the number of occurrences of hypertension and recognizing the correlation between the duration of the use of β2 agonists with hypertension event.Results: The incidence of hypertension in patients with asthma who were treated with beta-2 agonists are 50, 93% at the stage of pre-hypertension (120 mm Hg/80 mm Hg) and 25, 9% in stage I hypertension (140 mmHg/90 mmHg). Body weight and duration of therapy with a β2 agonist positively correlated with the incidence of hypertension with a correlation coefficient (r) 0.231 and 0.386 respectively. Conclusion:In this study, duration of therapy with a β2 agonist in asthma patients positively correlated with the incidence of hypertension.

show abstract

“…Adults with intermittent asthma begin with Step 1 therapy, which includes an inhaled SABA such as albuterol to use every 4 to 6 hours as needed for asthma symptoms (Table ) . SABAs relax the smooth muscle of the airways by stimulating beta 2 adrenergic receptors . The onset of action of albuterol is within 5 minutes, and the half‐life of the medication is between 4 and 6 hours with a peak effect between 30 and 60 minutes …”

Section: Stepwise Approach For Managing Asthmamentioning

confidence: 99%

Diagnosis and Treatment of Asthma in Nonpregnant Women

Esden¹,

Pesta-Walsh²

2018

J Midwife Womens Health

View full text Add to dashboard Cite

Asthma is a common condition affecting 8.3% of the adult population in the United States. The disease is characterized by chronic airway inflammation that leads to airway hyperresponsiveness and obstruction that results in coughing, wheezing, shortness of breath, and a feeling of chest tightness. The diagnosis and classification of asthma is based on reported symptoms, physical examination findings, and spirometry. Pharmacologic therapy is prescribed using a stepwise approach that begins with inhaled short-acting beta 2 -agonists for intermittent asthma with the addition of daily inhaled corticosteroids for more persistent cases. Individuals with asthma are reevaluated on a regular basis to monitor symptoms, and pharmacologic treatments are adjusted as needed. Familiarity with the stepwise approach for asthma management and confidence in the efficacy and safety profiles of inhaled medications will assist clinicians in successful management of asthma in the primary care setting. a low-dose inhaled corticosteroid in addition to a shortacting beta 2 -agonist to use as needed for acute symptoms. The clinician demonstrated inhaler usage, provided teaching on avoiding asthma triggers, and developed a written asthma action plan with C.E. A follow-up appointment was scheduled for 4 weeks.Note: This case summary is a composite of elements from different individuals. PATHOPHYSIOLOGYThe pathophysiology of asthma is complex in nature. The primary feature is airway inflammation caused by 18 1526-9523/09/$36.00

show abstract

Beta-Adrenergic Agonists

Cited by 83 publications

References 172 publications

β‐Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation

β‐Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation

Incidence of Hypertension in Asthma Patients Who Treated With Beta-2 Agonists Bronchodilators

Diagnosis and Treatment of Asthma in Nonpregnant Women

Contact Info

Product

Resources

About